Adults Ph negative acute lymphoblastic leukemia
Conditions
Interventions
Exeprimental group:Protocol of pegaspargase, cyclophosphamide, demethyl daunorubicin, vindesine and dexamethasone
Control group:Protocol of pegaspargase, cyclophosphamide, daunorubicin, vindesine and dexamethasone
Sponsors
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign an informed consent form. 2. Male or femal with age from 14 to 70 years 3. Newly diagnosed Ph negative acute lymphoblastic leukemia 4. The estimated survival is over three months 5. Adequate main organ function: (1) Liver: ALT/AST 40 %. 6. Karnofsky =60 at study entry
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding female subject; 2. Drug abusers; 3. uncontrolled infection 4 weeks before enrolled; 4. Known positive for HIV or acute infectious hepatitis, type A, B or C; 5. other primary tumor except for ALL; 6. Serious autoimmune disease or mmune deficiency disorder; 7. Central nervous involvement; 8. Serious psychiatric or psychological disorders; 9. Patients can not be enrolled judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of minimal residual disease negativity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of complete remission; | — |
Countries
China
Contacts
Public ContactXi Zhang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Outcome results
None listed